IMODI (Innovative MODels Initiative) is a French consortium, involving both academic and private partners. The goal of the consortium is to develop new experimental models for the diagnosis and treatment in cancer. The IMODI project includes 4 observational clinical studies in breast, ovary, prostate, and liver cancers. As part of the scientific valorization of IMODI, we recently focused our efforts on the breast cancer study, conducted by 2 referral cancer centers (Centre Léon-Bérard in Lyon and Centre Georges François Leclerc in Dijon). This led to the submission of 4 conference abstracts since January 2019.
A first poster was presented at the Cancéropôle Grand-Ouest congress in Tours in July 2019. It described the breast cancer cohort at recruitment, including some differences in demographic factors, life habits, and clinical parameters between localized and metastatic cancers.
In June, another poster was presented at the Mibiogate congress in Nantes. It focused on the characterization of the fecal microbiota taxonomic profiles in patients with a primodiagnosis of localized breast cancer at recruitment. It highlighted some differences according to body mass index, clinical stage, and menopausal status. An updated version of this data set will be presented in November at MIBIOC meeting in Milan, Italy.
A last abstract, presented at NutrEvent (Rennes, France), describes the dietary habits at recruitment of the patients in the former abstract. These women exhibited some variations in their dietary habits according to their BMI, clinical stages, menopausal status and sport activity.
The different parameters analyzed in these abstracts will be confronted to each other to unravel some potential correlations between them (e.g. fecal microbiota & diet). Furthermore, all the data generated by the consortium will be analyzed by using an Artificial Intelligence-based data mining platform, thus enabling extraction of new actionable hypotheses."